| Original language | English (US) |
|---|---|
| Pages (from-to) | 1112-1115 |
| Number of pages | 4 |
| Journal | Journal of Thrombosis and Haemostasis |
| Volume | 19 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2021 |
Keywords
- DOAC reversal
- anticoagulant reversal
- bleeding management
- hemostatic effectiveness
- major bleed
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Thrombosis and Haemostasis, Vol. 19, No. 4, 04.2021, p. 1112-1115.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Definition of haemostatic effectiveness in interventions used to treat major bleeding
T2 - Communication from the ISTH SSC Subcommittee on Control of Anticoagulation
AU - Khorsand, Nakisa
AU - Beyer-Westendorf, Jan
AU - Sarode, Ravi
AU - Schulman, Sam
AU - Meijer, Karina
N1 - Funding Information: Dr. N. Khorsand: grants and speaker fees from Sanquin and travel support from Bayer. Prof. J. Beyer‐Westendorf: speaker and advisory board fees from Bayer, Daiichi Sankyo, Portola, Pfizer; institutional research support from Bayer, Daiichi Sankyo, Portola, Pfizer, Boehringer Ingelheim, Takeda. Prof. Dr. R. Sarode: consultant Octapharma and CSL Behring, advisor to Portola, institutional research support from Siemens. Prof. Dr.K. Meijer: grants, speaker fees, and travel support from Bayer; grants and speaker fees from Sanquin; grants from Pfizer; speaker fees from Boehringer Ingelheim; speaker fees from BMS; speaker fees from Aspen; consulting fees from Uniqure. Prof. Dr. Schulman: grants from Octapharma, grants and personal fees from Boehringer Ingelheim, personal fees from Alnylam, personal fees from Bayer, personal fees from Bristol‐Myers Squibb, personal fees from Daiichi‐Sankyo, personal fees from Sanofi, outside the submitted work. Funding Information: We would like to acknowledge Rahat Abdoellakhan, Pharm.D, for reading and valuably commenting on this manuscript.
PY - 2021/4
Y1 - 2021/4
KW - DOAC reversal
KW - anticoagulant reversal
KW - bleeding management
KW - hemostatic effectiveness
KW - major bleed
UR - http://www.scopus.com/inward/record.url?scp=85103410051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103410051&partnerID=8YFLogxK
U2 - 10.1111/jth.15222
DO - 10.1111/jth.15222
M3 - Article
C2 - 33792175
AN - SCOPUS:85103410051
SN - 1538-7933
VL - 19
SP - 1112
EP - 1115
JO - Journal of Thrombosis and Haemostasis
JF - Journal of Thrombosis and Haemostasis
IS - 4
ER -